Inhibrx Gross Profit Trend from 2010 to 2022

INBX -  USA Stock  

USD 27.89  3.59  11.40%

Inhibrx Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 14.5 M in 2022. During the period from 2010 to 2022, Inhibrx Gross Profit regression line of anual values had slope of 536,026 and arithmetic mean of  10,213,167. Income Tax Expense is likely to rise to 2,771 in 2022, whereas Consolidated Income is likely to drop (73.9 M) in 2022.

Inhibrx Historical Trends 

 
Refresh
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx main balance sheet or income statement drivers, such as Gross Profit of 14.5 M, Interest Expense of 10 M or Net Income to Non Controlling Interests of 127.1 K, as well as many exotic indicators such as Asset Turnover of 0.14, Book Value per Share of 3.71 or Current Ratio of 5.22. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules. It can also supplement various Inhibrx Technical models. Please see the analysis of Inhibrx Correlation against competitors.

Inhibrx Quarterly Gross Profit

2.53 MillionShare

Inhibrx Gross Profit Breakdown

Showing smoothed Gross Profit of Inhibrx with missing and latest data points interpolated. Gross profit is a required income statement account that reflects total revenue of Inhibrx minus its cost of goods sold. It is profit before Inhibrx operating expenses, interest payments and taxes. Gross profit is also known as gross margin. Aggregate revenue Revenues less cost of revenue [CoR] directly attributable to the revenue generation activity.Inhibrx's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (60.61 M)10 Years Trend
Increasing
Slightly volatile
 Gross Profit 
Share
      Timeline 

Inhibrx Gross Profit Regression Statistics

Arithmetic Mean 10,213,167
Geometric Mean 9,949,585
Coefficient Of Variation 25.17
Mean Deviation 2,240,538
Median 8,595,000
Standard Deviation 2,570,412
Range 6,226,200
R-Value 0.81
R-Squared 0.66
Significance 0.00074469
Slope 536,026

Inhibrx Gross Profit History

201913.2 M
202012.9 M
202114.8 M
202214.5 M

About Inhibrx Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inhibrx income statement, its balance sheet, and the statement of cash flows. Inhibrx investors use historical funamental indicators, such as Inhibrx's Gross Profit, to determine how well the company is positioned to perform in the future. Although Inhibrx investors may use each financial statement separately, they are all related. The changes in Inhibrx's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inhibrx's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inhibrx Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Gross Profit14.8 M14.5 M
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Inhibrx Investors Sentiment

The influence of Inhibrx's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inhibrx. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inhibrx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inhibrx's short interest history, or implied volatility extrapolated from Inhibrx options trading.

Current Sentiment - INBX

Inhibrx Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Inhibrx. What is your judgment towards investing in Inhibrx? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inhibrx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inhibrx Correlation against competitors. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.